Hong Kong Stock Market Mover | Nuohua Health (09969.HK) surged more than 6% in early trading BCL2 inhibitor Mesutoclax approved for clinical use in the United States to treat AML and MDS

According to the Securities Times app, Nou Chen Jianhua (09969.HK) rose more than 6% in early trading, up 5.24% as of the time of the report, to 17.26 Hong Kong dollars, with a turnover of 194 million Hong Kong dollars.